Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ascendis Pharma A/S stock

Own Ascendis Pharma A/S stock in just a few minutes.

Ascendis Pharma A/S is a biotechnology business based in the US. Ascendis Pharma A/S shares (ASND) are listed on the NASDAQ and all prices are listed in US Dollars. Ascendis Pharma A/S employs 482 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Ascendis Pharma A/S

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ASND – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Ascendis Pharma A/S share price

Use our graph to track the performance of ASND stocks over time.

Ascendis Pharma A/S shares at a glance

Information last updated 2021-04-29.
52-week range$119.11 - $183.98
50-day moving average $133.08
200-day moving average $154.67
Wall St. target price$194.97
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.09

Buy Ascendis Pharma A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ascendis Pharma A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ascendis Pharma A/S financials

Revenue TTM $7 million
Gross profit TTM $7 million
Return on assets TTM -24.95%
Return on equity TTM -58.36%
Profit margin 0%
Book value $15.60
Market capitalisation $7.4 billion

TTM: trailing 12 months

Shorting Ascendis Pharma A/S shares

There are currently 3.0 million Ascendis Pharma A/S shares held short by investors – that's known as Ascendis Pharma A/S's "short interest". This figure is 2.8% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Ascendis Pharma A/S shares can be evaluated.

Ascendis Pharma A/S's "short interest ratio" (SIR)

Ascendis Pharma A/S's "short interest ratio" (SIR) is the quantity of Ascendis Pharma A/S shares currently shorted divided by the average quantity of Ascendis Pharma A/S shares traded daily (recently around 241751.92926045). Ascendis Pharma A/S's SIR currently stands at 12.44. In other words for every 100,000 Ascendis Pharma A/S shares traded daily on the market, roughly 12440 shares are currently held short.

However Ascendis Pharma A/S's short interest can also be evaluated against the total number of Ascendis Pharma A/S shares, or, against the total number of tradable Ascendis Pharma A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ascendis Pharma A/S's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ascendis Pharma A/S shares in existence, roughly 60 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Ascendis Pharma A/S shares, roughly 0 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ascendis Pharma A/S.

Find out more about how you can short Ascendis Pharma A/S stock.

Ascendis Pharma A/S share dividends

We're not expecting Ascendis Pharma A/S to pay a dividend over the next 12 months.

Ascendis Pharma A/S share price volatility

Over the last 12 months, Ascendis Pharma A/S's shares have ranged in value from as little as $119.11 up to $183.98. A popular way to gauge a stock's volatility is its "beta".

ASND.US volatility(beta: 0.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ascendis Pharma A/S's is 0.7375. This would suggest that Ascendis Pharma A/S's shares are less volatile than average (for this exchange).

Ascendis Pharma A/S overview

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. .

Frequently asked questions

What percentage of Ascendis Pharma A/S is owned by insiders or institutions?
Currently 0.026% of Ascendis Pharma A/S shares are held by insiders and 103.063% by institutions.
How many people work for Ascendis Pharma A/S?
Latest data suggests 482 work at Ascendis Pharma A/S.
When does the fiscal year end for Ascendis Pharma A/S?
Ascendis Pharma A/S's fiscal year ends in December.
Where is Ascendis Pharma A/S based?
Ascendis Pharma A/S's address is: Tuborg Boulevard 12, Hellerup, Denmark, 2900
What is Ascendis Pharma A/S's ISIN number?
Ascendis Pharma A/S's international securities identification number is: US04351P1012
What is Ascendis Pharma A/S's CUSIP number?
Ascendis Pharma A/S's Committee on Uniform Securities Identification Procedures number is: 04351P101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site